UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth.
Andrew L WolfeQingwen ZhouEneda ToskaJacqueline GaleasAngel A KuRichard P KocheSourav BandyopadhyayMaurizio ScaltritiCarlito B LebrillaFrank McCormickSung Eun KimPublished in: Proceedings of the National Academy of Sciences of the United States of America (2021)
UDP-glucose pyrophosphorylase 2 (UGP2), the enzyme that synthesizes uridine diphosphate (UDP)-glucose, rests at the convergence of multiple metabolic pathways, however, the role of UGP2 in tumor maintenance and cancer metabolism remains unclear. Here, we identify an important role for UGP2 in the maintenance of pancreatic ductal adenocarcinoma (PDAC) growth in both in vitro and in vivo tumor models. We found that transcription of UGP2 is directly regulated by the Yes-associated protein 1 (YAP)-TEA domain transcription factor (TEAD) complex, identifying UGP2 as a bona fide YAP target gene. Loss of UGP2 leads to decreased intracellular glycogen levels and defects in N-glycosylation targets that are important for the survival of PDACs, including the epidermal growth factor receptor (EGFR). These critical roles of UGP2 in cancer maintenance, metabolism, and protein glycosylation may offer insights into therapeutic options for otherwise intractable PDACs.
Keyphrases
- epidermal growth factor receptor
- transcription factor
- papillary thyroid
- tyrosine kinase
- blood glucose
- advanced non small cell lung cancer
- small cell lung cancer
- squamous cell
- type diabetes
- squamous cell carcinoma
- genome wide
- skeletal muscle
- dna methylation
- blood pressure
- childhood cancer
- reactive oxygen species
- genome wide identification
- gene expression
- metabolic syndrome
- binding protein
- free survival